Advanced Practice Providers Oncology Summit.

Emerging Technologies for the Management of Colon Cancer

Overview

Colon cancer is the 3rd most common cancer in the US and ranks 2nd as the cause of cancer-related deaths overall. Participants will improve their understanding of how tumor profiles and biomarker analysis can assist in selecting targeted therapies for patients with colon cancer. Experts will also discuss the evidence available for circulating tumor DNA assays and they can detect minimal residual disease in colorectal cancer patients.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Describe how to use tumor profile, biomarker analysis, and patient-specific characteristics to select targeted therapies for individuals with colon cancer
2. Review the evidence for use of circulating tumor (ct) DNA assays in detecting minimal residual disease in patients with colorectal cancer

Faculty: Nancy Wipf, DNP, MSN, MEd, FNP-BC, AOCNP

Credit Hours: CREDIT HOURS: .75 AMA PRA Category 1 Credit™ .75 ANCC

Course Expires: 9.8.2024

Similar Courses To Consider

Melanoma Management in 2024

Advanced Practice Providers Oncology Summit. ONCOLOGY ON DEMAND LIBRARY Melanoma Management in 2024 Overview This program offers a focused exploration of the standard guidelines and best practices

VIEW COURSE »